Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Intensity Therapeutics, Inc. ( (INTS) ).
On June 6, 2025, Intensity Therapeutics, Inc. received a notification from Nasdaq indicating that its common stock had not maintained the minimum closing bid price of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). This notice does not immediately affect the company’s stock listing or trading, and the company has until December 3, 2025, to regain compliance. Intensity Therapeutics plans to monitor its stock price and explore options to meet the requirement, although there is no guarantee of success or further extension from Nasdaq.
The most recent analyst rating on (INTS) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Average Trading Volume: 519,925
Technical Sentiment Signal: Sell
Find detailed analytics on INTS stock on TipRanks’ Stock Analysis page.